Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 13/20 | 0.73 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.73 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.73 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.73 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.73 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.73 |
| ▸ | HTR3A | P46098 | 2/20 | 0.50 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28004517 | 1.00 | SLC6A2 (0.73) | SLC6A2SLC6A4OPRM1OPRD1SLC22A1 | |
| SCHEMBL29965897 | 1.00 | SLC6A2 (0.73) | SLC6A2SLC6A4OPRM1OPRD1SLC22A1 | |
| SCHEMBL159543 | 0.90 | SLC6A2 (0.63) | SLC6A2SLC6A4OPRM1OPRD1SLC22A1 | |
| SCHEMBL29966428 | 0.90 | SLC6A2 (0.63) | SLC6A2SLC6A4OPRM1OPRD1SLC22A1 | |
| SCHEMBL20473750 | 0.90 | SLC6A2 (0.63) | SLC6A2SLC6A4OPRM1OPRD1SLC22A1 | |
| SCHEMBL15654221 | 0.90 | SLC6A2 (0.63) | SLC6A2SLC6A4OPRM1OPRD1SLC22A1 | |
| SCHEMBL19461051 | 0.89 | OPRM1 (0.62) | SLC6A2SLC6A4OPRM1OPRD1SLC22A1 | |
| SCHEMBL159730 | 0.89 | OPRM1 (0.62) | SLC6A2SLC6A4OPRM1OPRD1SLC22A1 | |
| SCHEMBL17506037 | 0.89 | OPRM1 (0.62) | SLC6A2SLC6A4OPRM1OPRD1SLC22A1 | |
| SCHEMBL29966537 | 0.89 | OPRM1 (0.62) | SLC6A2SLC6A4OPRM1OPRD1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6894076-B2 | Esters derived from (RR,SS)-2-hydroxybenzoate of 3-(2-dimethylaminomethyl-1-hydroxycyclohexyl)phenyl | VITA-INVEST, S.A. (ES) | 2005-05-17 | — | — | US | claimed |
| EP-1251120-B1 | ESTERS DERIVED FROM (RR,SS)-2-HYDROXYBENZOATE OF 3-(2-DIMETHYLAMINOMETHYL-1-HYDROXYCYCLOHEXYL)PHENYL | VITA LAB (ES) | 2004-12-08 | — | — | EP | claimed |
| EP-1251120-A1 | NOVEL ESTERS DERIVED FROM (RR,SS)-2-HYDROXYBENZOATE OF 3-(2-DIMETHYLAMINOMETHYL-1-HYDROXYCYCLOHEXYL)PHENYL | VITA-INVEST, S.A. (ES) | 2002-10-23 | — | — | EP | claimed |
| US-11844865-B2 | Abuse-proofed oral dosage form | Grünenthal GmbH (DE) | 2023-12-19 | — | — | US | disclosed |
| US-11224576-B2 | Process for the production of an abuse-proofed dosage form | Grünenthal GmbH (DE) | 2022-01-18 | — | — | US | disclosed |
| US-20210046009-A1 | PROTECTING ORAL OVERDOSE WITH ABUSE DETERRENT IMMEDIATE RELEASE FORMULATIONS | Grünenthal GmbH (DE) | 2021-02-18 | — | — | US | disclosed |
| US-20200397704-A1 | ABUSE-PROOFED ORAL DOSAGE FORM | Grünenthal GmbH (DE) | 2020-12-24 | — | — | US | disclosed |
| US-10864164-B2 | Tamper-resistant tablet providing immediate drug release | Grünenthal GmbH (DE) | 2020-12-15 | — | — | US | disclosed |
| US-10842750-B2 | Protecting oral overdose with abuse deterrent immediate release formulations | Grünenthal GmbH (DE) | 2020-11-24 | — | — | US | disclosed |
| US-20200338069-A1 | TAMPER-RESISTANT DOSAGE FORM WITH IMMEDIATE RELEASE AND RESISTANCE AGAINST SOLVENT EXTRACTION | Grünenthal GmbH (DE) | 2020-10-29 | — | — | US | disclosed |
| US-20200276188-A1 | TAMPER-RESISTANT DOSAGE FORM WITH IMMEDIATE RELEASE AND RESISTANCE AGAINST SOLVENT EXTRACTION | Grünenthal GmbH (DE) | 2020-09-03 | — | — | US | disclosed |
| US-20060193914-A1 | Crush resistant delayed-release dosage forms | ENDO PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | disclosed |
| US-20060193782-A1 | Abuse-proofed dosage form | ENDO PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | disclosed |
| US-20060002860-A1 | Abuse-proofed oral dosage form | ENDO PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
| US-20050249792-A1 | Active ingredient release system comprising a plaster containing an active ingredient and at least one active ingredient release regulator | GRUENENTHAL GMBH (DE) | 2005-11-10 | — | — | US | disclosed |
| US-20050236741-A1 | Process for the production of an abuse-proofed solid dosage form | ENDO PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| US-6894076-B2 | Esters derived from (RR,SS)-2-hydroxybenzoate of 3-(2-dimethylaminomethyl-1-hydroxycyclohexyl)phenyl | VITA-INVEST, S.A. (ES) | 2005-05-17 | — | — | US | disclosed |
| US-20050031546-A1 | Abuse-proffed dosage form | ENDO PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | disclosed |
| EP-1251120-B1 | ESTERS DERIVED FROM (RR,SS)-2-HYDROXYBENZOATE OF 3-(2-DIMETHYLAMINOMETHYL-1-HYDROXYCYCLOHEXYL)PHENYL | VITA LAB (ES) | 2004-12-08 | — | — | EP | disclosed |
| EP-1251120-A1 | NOVEL ESTERS DERIVED FROM (RR,SS)-2-HYDROXYBENZOATE OF 3-(2-DIMETHYLAMINOMETHYL-1-HYDROXYCYCLOHEXYL)PHENYL | VITA-INVEST, S.A. (ES) | 2002-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10864164-B2 | Tamper-resistant tablet providing immediate drug release | TNNC1, PTGER3, PTGIR | SLC6A2 972/4885SLC6A4 401/4885OPRM1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.